MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease

    M. Facheris, D. Ysselstein, J. van Dervalk, E. Thijssen, L. Pagan, G. Valstar, C. Schotborgh, P. Kremer, M. Hagey, J. Cederbaum, J. Sullivan, K. Hunt, O. Siddiqui (Chicago, USA)

    Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…
  • 2025 International Congress

    The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease

    I. Malaty, P. Odin, D. Kern, L. Bergmann, M. Shah, R. Gupta, A. Antonini, K. Chaudhuri (Gainesvile, USA)

    Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…
  • 2025 International Congress

    Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures

    N. Elayan, L. Rubin, M. Mccrossin, C. Roberts, H. Shakil, A. Di Rocco, M. Ghilardi (Long Island, USA)

    Objective: In this study, we wish to determine whether medication changes play a major role in the improvements observed after in-patient multimodal intensive neurorehabilitation and…
  • 2025 International Congress

    Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson’s disease

    R. de Fiores, I. Martino, A. Quattrone, B. Vescio, G. Arabia, A. Gambardella, M. Morelli (Catanzaro, Italy)

    Objective: We aim to evaluate the efficacy of Opicapone (OPC) on end-of-dose neuropsychiatric fluctuations, the most frequent and severe non-motor fluctuations (NMF) in Parkinson’s disease (PD) patients [1].…
  • 2025 International Congress

    Evaluation of the Pharmacodynamic Effects of BIIB122/DNL151 in Participants with LRRK2 mutation-driven Parkinson’s disease (BEACON Study)

    J. Kluss, S. Huntwork-Rodriguez, D. Jennings, S. Ota, R. Maciuca, J. Alkabsh, S. Davis, J. Suh, M. Schwarzschild, K. Fraser, R. Llorens-Arenas, C. Ho, P. Chin (South San Francisco, USA)

    Objective: To characterize the biomarker effects of BIIB122/DNL151 in participants with LRRK2 pathogenic mutations diagnosed with Parkinson’s disease (LRRK2-PD). Background: BIIB122/DNL151 is a CNS-penetrant small…
  • 2025 International Congress

    Plasma Protein Profiles Reveal Distinct Molecular Signatures in Parkinson’s Disease and Multiple System Atrophy

    SJ. Chung, S. Jo, I. Jang, J. Lee, M. Choi, E. Lee (Seoul, Republic of Korea)

    Objective: We aimed to identify distinct plasma proteins in patients with Parkinson’s disease (PD) and multiple system atrophy (MSA) and evaluate their associations with disease…
  • 2025 International Congress

    A Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes (proATYP).

    M. Makrygianni, D. Potamianou, T. Pipikos, M. Xilouri, C. Mourmouris, A. Sarafi, L. Florentin, M. Stamelou (Athens, Greece)

    Objective: This is a prospective observational study to identify biomarkers in parkinsonian syndromes. Background: Parkinson’s disease (PD) and atypical parkinsonian syndromes namely progressive supranuclear palsy…
  • 2025 International Congress

    Glossography – a novel, computer-vision based technique for assessing and treating involuntary tongue movements in dyskinetic episodes in Parkinson’s disease

    M. Brzezicki, M. Palczynski, E. Pilchowska-Ujma, O. Szymańska-Adamcewicz, N. Pawlak, P. Lesniak, S. Jurga (Oxford, United Kingdom)

    Objective: To develop and evaluate a novel deep learning-based computer vision approach for tracking tongue movements in Parkinson's disease (PD) patients with levodopa-induced dyskinesias to…
  • 2025 International Congress

    Alpha-Synuclein Preformed Fibrils Increase the Frequency of CXCR3+ B-cells in Early-stage Parkinson’s Disease Patients

    H. Hong, M. Dean, D. Standaert, H. Qin, E. Benveniste (Birmingham, USA)

    Objective: To investigate the effect of a-Syn Preformed Fibrils (PFF) on CXCR3 expression on B-cells in Parkinson’s Disease (PD) patients at early (E-PD, diagnosed less…
  • 2025 International Congress

    Determinants of Cognitive Progression in Parkinson’s Disease: A Machine Learning Approach

    AJ. Hernández-Medrano, A. Cervantes-Arriaga, MF. Medina-Pérez, D. Ulloa-Hernández, MF. Velasco-Delgado, GA. Martin-Mafud, AE. López-Lobato, D. Náfate-Wences, M. Rodríguez-Violante (Mexico City, Mexico)

    Objective: To identify clinical and sociodemographic factors associated with cognitive decline (CD) in PD using a Random Forests model, classifying people with PD (PwP) into…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley